Skip to main content
. 2016 May 20;102(17):1342–1347. doi: 10.1136/heartjnl-2014-306775

Figure 3.

Figure 3

Effect of sacubitril/valsartan on the rate of primary end point and component and all-cause mortality in patients randomised in the PARADIGM-HF trial according to age group.27 p for interaction for cardiovascular (CV) death or heart failure (HF) hospitalisation=0.94, for CV death p for interaction=0.92, for HF hospitalisation p for interaction=0.81 and all-cause death p for interaction=0.99. PARADIGM-HF, Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure.